Azurity Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AZURITY, and when can generic versions of AZURITY drugs launch?
AZURITY has twenty-three approved drugs.
There are seventy-eight US patents protecting AZURITY drugs.
There are three hundred and thirty-five patent family members on AZURITY drugs in forty-eight countries and forty-one supplementary protection certificates in fifteen countries.
Summary for Azurity
| International Patents: | 335 |
| US Patents: | 78 |
| Tradenames: | 23 |
| Ingredients: | 22 |
| NDAs: | 23 |
| Patent Litigation for Azurity: | See patent lawsuits for Azurity |
Drugs and US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | EPANED | enalapril maleate | SOLUTION;ORAL | 208686-001 | Sep 20, 2016 | AB | RX | Yes | Yes | 11,141,405 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Azurity | ERYPED | erythromycin ethylsuccinate | GRANULE;ORAL | 050207-003 | Mar 30, 1987 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Azurity | SOTYLIZE | sotalol hydrochloride | SOLUTION;ORAL | 205108-001 | Oct 22, 2014 | RX | Yes | Yes | 11,013,703 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-001 | Feb 25, 2011 | 5,583,141 | ⤷ Try a Trial |
| Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-004 | Jan 30, 2019 | 10,130,580 | ⤷ Try a Trial |
| Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-002 | Feb 25, 2011 | 5,583,141 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AZURITY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 1 mg/mL | ➤ Subscribe | 2018-08-31 |
International Patents for Azurity Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2296956 | ⤷ Try a Trial |
| Canada | 2538802 | ⤷ Try a Trial |
| Poland | 2500014 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Azurity Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0678503 | C300499 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114 |
| 1718641 | 132012902056823 | Italy | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL(EDARBI E IPREZIV); AUTHORISATION NUMBER(S) AND DATE(S): EDARBI: DA EU/1/11/734/001 A EU/1/11/734/011; IPREZIV: DA EU/1/11/735/001 A EU/1/11/735/011, 20111207 |
| 2317997 | 2190050-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
